sur Darwin AG (isin : DE000A3C35W0)
Darwin AG Reports Significant Revenue Growth for 2025
Darwin AG, a prominent European healthcare company, has announced its preliminary group revenue for 2025, showcasing significant growth. The company recorded consolidated revenue of approximately €55 million, a 117% increase from the previous year's €25.3 million. This impressive growth underscores the operational strength of the group, according to CEO Dr. Daniel Wallerstorfer.
Key contributors to this expansion include the successful international marketing of genetic analysis products and personalized nutritional supplements through its subsidiary, Novogenia GmbH. Strategic partnerships with 10X Health (USA) and M42 (Abu Dhabi) are cited as instrumental in this scaling phase. Darwin AG anticipates continued value creation through these partnerships and future initiatives.
The audited financial figures for 2025 will be published alongside the Annual Report on May 12, 2026.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Darwin AG